Olema Pharmaceuticals, Inc. has changed its corporate name to Olema Oncology, Inc. and relocated its principal executive offices to South San Francisco. The company's common stock will continue to trade on the Nasdaq Global Select Market under the existing ticker symbol OLMA.
Olema Pharmaceuticals reported a net loss of $189.9 million for the first nine months of 2026, compared to $116.4 million in the prior year, driven by a significant increase in research and development expenses. The company maintained a strong liquidity position with $413.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026.
Olema Pharmaceuticals reported a net loss of $73.6 million for the third quarter of 2026, driven by increased clinical trial enrollment costs. The company ended the period with $413.8 million in cash and remains on track to report pivotal Phase 3 OPERA-01 data in the first quarter of 2027.
Term
Q3 2026
“As we approach top-line data from our pivotal Phase 3 OPERA-01 trial in the first quarter of 2027, we remain confident in palazestrant’s potential to emerge as a differentiated endocrine therapy in second- and third-line metastatic breast cancer.”
Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer
“We believe that palazestrant, in combination with ribociclib, is well positioned to become the new standard of care in this setting. With its dual mechanism of action as a complete estrogen receptor antagonist and selective estrogen receptor degrader, optimal pharmacokinetic properties, encouraging clinical profile demonstrated to date, and potential for use both as a monotherapy and in combination with other agents, we believe palazestrant is uniquely positioned to transform the metastatic breast cancer treatment paradigm.”
Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer
Dr. Gorjan Hrustanovic resigned from the Board of Directors and its committees effective October 14, 2026, noting no disagreements with the company. Dr. Prakash Raman was subsequently appointed to the Compensation and Science and Technology Committees to fill the vacancies.